Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Commitments and Contingencies (Details Textual)

v3.21.2
Note 7 - Commitments and Contingencies (Details Textual)
3 Months Ended 6 Months Ended
Mar. 16, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Sublease Income   $ 10,000 $ 10,000 $ 21,000 $ 21,000
Operating Lease, Payments   34,000 33,000 68,000 66,000
License Agreements Expense   56,000 61,000 94,000 122,000
Research and Development Expense, Total   3,039,000 3,329,000 7,145,000 6,535,000
MD Anderson [Member]          
Research and Development Expense, Total   184,000 212,000 278,000 358,000
Houston Pharmaceuticals, Inc [Member]          
Other Commitments, Number of Agreements 2        
Related Party Transaction, Expenses from Transactions with Related Party   $ 59,000 $ 59,000 $ 117,000 $ 167,000
Houston Pharmaceuticals, Inc [Member] | Consulting Agreement on Licensed Molecules [Member]          
Other Commitments, Term (Year) 2 years        
Other Commitment, Total $ 43,500        
Houston Pharmaceuticals, Inc [Member] | Agreement Providing Access to Laboratory Equipment [Member]          
Other Commitment, Total $ 15,000        
Other Commitments, Cancellation Period (Day) 60 days